Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection.


Journal

Nature aging
ISSN: 2662-8465
Titre abrégé: Nat Aging
Pays: United States
ID NLM: 101773306

Informations de publication

Date de publication:
06 2022
Historique:
received: 19 08 2021
accepted: 14 04 2022
medline: 1 5 2023
pubmed: 29 4 2023
entrez: 28 4 2023
Statut: ppublish

Résumé

We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facilities developed high and stable levels of antibodies against spike protein and receptor-binding domain. Nucleocapsid-specific responses were also elevated but waned over time. Antibodies showed stable and equivalent levels of functional inhibition against spike-angiotensin-converting enzyme 2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or other respiratory syncytial viruses. SARS-CoV-2-specific cellular responses were similar across all ages but virus-specific populations showed elevated levels of activation in older donors. Thus, survivors of SARS-CoV-2 infection show a robust and stable immunity against the virus that does not negatively impact responses to other seasonal viruses.

Identifiants

pubmed: 37118449
doi: 10.1038/s43587-022-00224-w
pii: 10.1038/s43587-022-00224-w
pmc: PMC10154219
doi:

Substances chimiques

Influenza Vaccines 0
Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

536-547

Subventions

Organisme : Wellcome Trust
ID : 222907/Z/21/Z
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

SN Compr Clin Med. 2020;2(12):2658-2669
pubmed: 33169110
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Lancet Infect Dis. 2021 Nov;21(11):1529-1538
pubmed: 34174193
Sci Immunol. 2019 Nov 1;4(41):
pubmed: 31672862
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
J Infect. 2020 Sep;81(3):411-419
pubmed: 32504743
Nat Immunol. 2022 Jan;23(1):40-49
pubmed: 34937928
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Immun Ageing. 2021 Feb 17;18(1):7
pubmed: 33596958
PLoS Med. 2021 Jul 6;18(7):e1003656
pubmed: 34228725
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Nat Rev Cardiol. 2018 Sep;15(9):505-522
pubmed: 30065258
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Nat Rev Immunol. 2006 Oct;6(10):741-50
pubmed: 16977339
Age Ageing. 2021 Jun 28;50(4):1019-1028
pubmed: 33710281
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Lancet Healthy Longev. 2021 Sep;2(9):e544-e553
pubmed: 34430954
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Wellcome Open Res. 2020 Oct 7;5:232
pubmed: 33564722
Euro Surveill. 2021 Feb;26(5):
pubmed: 33541486
Science. 2019 Nov 1;366(6465):599-606
pubmed: 31672891
Age Ageing. 2021 Jan 8;50(1):25-31
pubmed: 32951042
Sci Rep. 2021 Feb 23;11(1):4358
pubmed: 33623057
Lancet Healthy Longev. 2021 Jun;2(6):e362-e370
pubmed: 34104901
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-2230
pubmed: 32687551
BMC Med. 2021 Mar 5;19(1):71
pubmed: 33663498
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637

Auteurs

Gokhan Tut (G)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. g.tut@bham.ac.uk.

Tara Lancaster (T)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Megan S Butler (MS)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Panagiota Sylla (P)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Eliska Spalkova (E)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

David Bone (D)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Nayandeep Kaur (N)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Christopher Bentley (C)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Umayr Amin (U)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Azar T Jadir (AT)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Samuel Hulme (S)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Morenike Ayodel (M)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Alexander C Dowell (AC)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Hayden Pearce (H)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Jianmin Zuo (J)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Sandra Margielewska-Davies (S)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Kriti Verma (K)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Samantha Nicol (S)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Jusnara Begum (J)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Elizabeth Jinks (E)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Elif Tut (E)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Rachel Bruton (R)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Maria Krutikov (M)

UCL Institute of Health Informatics, London, UK.

Madhumita Shrotri (M)

UCL Institute of Health Informatics, London, UK.

Rebecca Giddings (R)

UCL Institute of Health Informatics, London, UK.

Borscha Azmi (B)

UCL Institute of Health Informatics, London, UK.

Chris Fuller (C)

UCL Institute of Health Informatics, London, UK.

Aidan Irwin-Singer (A)

Department of Health and Social Care, London, UK.

Andrew Hayward (A)

Health Data Research UK, London, UK.

Andrew Copas (A)

UCL Institute for Global Health, London, UK.

Laura Shallcross (L)

UCL Institute of Health Informatics, London, UK.

Paul Moss (P)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. p.moss@bham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH